Dark

Check out our Level2View

AIMT
Aimmune Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Oct 12, 2020

34.49USD-0.289%(-0.10)987,254

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Feb 25, 2021

09:06AM EST Aimmune Presents New Clinical Data From Pooled Safety Analysis In Patients Treated With PALFORZIA(r) For Up To 3.5 Years RTTNews

Nov 19, 2020

08:00AM EST Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information GlobeNewswire Inc

Oct 15, 2020

07:29PM EDT Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders PR Newswire

Oct 14, 2020

02:46AM EDT Nestle SA (NSRGY.PK, NSTR.L) announced the completion of its acquisition of Aimmune Therapeutics, Inc. (AIMT). Andrew Oxtoby has been named as Aimmune's President & CEO. He was previously Aimmune's Chief Commercial Officer. RTTNews

Oct 13, 2020

03:20AM EDT Nestle SA (NSRGY.PK, NSTR.L) said, in an update on results of tender offer for Aimmune Therapeutics (AIMT), that about 43.44 million Aimmune shares were validly tendered. It represented about 84% of the outstanding shares of Aimmune. RTTNews

02:42AM EDT Nestl Announces Results Of Tender Offer For Aimmune Therapeutics RTTNews

Sep 23, 2020

03:00PM EDT SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of GlobeNewswire Inc

07:00AM EDT - Longitude Venture Partners IV will build on the Firms commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - GlobeNewswire Inc

Sep 18, 2020

08:00PM EDT SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PR Newswire

Sep 17, 2020

04:31PM EDT ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders PR Newswire

Sep 16, 2020

01:25PM EDT Lifshitz Law Firm, P.C. Announces Investigation of Aimmune GlobeNewswire Inc

Sep 14, 2020

01:44AM EDT Nestl, S.A (NSRGY.OB) announced Monday that its unit Socits des Produits Nestl S.A, through SPN Merger Sub, Inc., is commencing a cash tender offer to buy Aimmune Therapeutics, Inc. (AIMT). RTTNews

01:21AM EDT Nestl Commences Tender Offer For Aimmune RTTNews

01:15AM EDT Nestl commences tender offer for Aimmune Therapeutics, Inc. PR Newswire

Sep 11, 2020

08:45PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its PR Newswire

Sep 10, 2020

08:50PM EDT Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial Corporation, Cancer Genetics, Inc., Proteostasis Therapeutics, Inc., Rosetta Stone Inc., and Yintech Investment Holdings Limited PR Newswire

Sep 5, 2020

08:30AM EDT Kaskela Law LLC Announces Stockholder Investigation of Aimmune Therapeutics, PR Newswire

Sep 4, 2020

07:37PM EDT AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ?? Aimmune Therapeutics Inc. - AIMT Business Wire

Sep 3, 2020

12:53PM EDT Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: GlobeNewswire Inc

Sep 1, 2020

11:17PM EDT Mergers; Shareholders are Encouraged to Contact the Firm - RST, CBMG, AIMT, MR PR Newswire

09:47AM EDT Benzinga's Top Upgrades, Downgrades For September 1, 2020 Benzinga

08:32AM EDT Credit Suisse Maintains Neutral on Aimmune Therapeutics, Raises Price Target to $34.5 Benzinga

08:06AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:19AM EDT Cantor Fitzgerald Downgrades Aimmune Therapeutics to Neutral, Raises Price Target to $35 Benzinga

05:46AM EDT Wedbush Downgrades Aimmune Therapeutics to Neutral, Lowers Price Target to $34.5 Benzinga

Aug 31, 2020

08:21PM EDT SHAREHOLDER ALERT: WeissLaw LLP Investigates Aimmune Therapeutics, Inc. PR Newswire

04:38PM EDT Hearing Wedbush Downgrades Aimmune From Outperform To Neutral Benzinga

02:30PM EDT Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Regis Shares Drop After Q4 Results Benzinga

12:37PM EDT AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. GlobeNewswire Inc

12:04PM EDT Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet Benzinga

12:01PM EDT ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aimmune Therapeutics, Inc. Business Wire

11:32AM EDT Piper Sandler Downgrades Aimmune Therapeutics to Neutral, Lowers Price Target to $34.5 Benzinga

10:11AM EDT Mid-Morning Market Update: Markets Mostly Lower; Nestl To Acquire Aimmune Therapeutics Benzinga

08:45AM EDT ROCE Insights For Aimmune Therapeutics Benzinga

07:38AM EDT (AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune PR Newswire

06:06AM EDT A Peek Into The Markets: US Stock Futures Gain Ahead Of Zoom Earnings Benzinga

05:30AM EDT Nestl to acquire Aimmune Therapeutics for $34.50/Share Benzinga

04:42AM EDT Aimmune Shares Surge 170% As Nestle Set To Acquire Company At $2.6B Enterprise Value Benzinga

01:44AM EDT Aimmune Therapeutics Inc. (AIMT) announced definitive agreement for Socits des Produits Nestl, S.A. to acquire the company for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value of $2.6 billion. The offer price represents 174% premium to Aimmune's closing price on August 28, 2020. RTTNews

01:24AM EDT Socits Des Produits Nestl, S.A. To Acquire Aimmune For $34.50 Per Share In An All-cash Transaction RTTNews

01:15AM EDT Aimmune Therapeutics Enters Definitive Agreement with Socits des Produits Nestl S.A., Part of Nestl Health Science Business Wire

Aug 27, 2020

09:18AM EDT AIM ImmunoTech Says Decreases SARS-CoV-2 Infectious Viral Yields By 90% Using New In Vitro Model; Says Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 Benzinga

09:17AM EDT Hearing AIM ImmunoTech Says Decreases SARS-CoV-2 Infectious Viral Yields By 90% Using New In Vitro Model; Says Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 Benzinga

09:17AM EDT AIM ImmunoTech Says Decreases SARS-CoV-2 Infectious Viral Yields By 90% Using New In Vitro Model; Says Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 Benzinga

Aug 24, 2020

08:50AM EDT Aimmune : APPEAL-2 Study Highlights Substantial Impact Of Peanut Allergy On Lives Of Children, Teenagers, And Caregivers RTTNews

08:41AM EDT Aimmune Therapeutics Highlights APPEAL-2 Study In Peanut Allergy Benzinga

08:30AM EDT Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers Business Wire

Aug 7, 2020

08:00AM EDT Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire

Jul 30, 2020

04:27PM EDT Aimmune Therapeutics Q2 EPS $(1.06) Beats $(1.09) Estimate Benzinga

04:06PM EDT Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights Business Wire

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 29, 2020

10:00AM EDT Credit Suisse Maintains Neutral on Aimmune Therapeutics, Lowers Price Target to $15 Benzinga

Jul 23, 2020

08:30AM EDT Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights Business Wire

Jul 21, 2020

08:36AM EDT Aimmune: Results Of Pivotal Phase 3 European ARTEMIS Trial Of PALFORZIA Published In Lancet Child & Adolescent Health RTTNews

08:30AM EDT Full Results of Aimmune's Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA(r) Published in The Lancet Child & Adolescent Health Business Wire

Jul 13, 2020

09:32AM EDT Benzinga's Top Upgrades, Downgrades For July 13, 2020 Benzinga

07:44AM EDT Cowen & Co. Initiates Coverage On Aimmune Therapeutics with Outperform Rating, Announces Price Target of $35 Benzinga

Share